Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.84 |
| ▸ | HNF4A | P41235 | 3/20 | 0.84 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.80 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.80 |
| ▸ | ACMSD | Q8TDX5 | 4/20 | 0.69 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.69 |
| ▸ | DHFR | P00374 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 5/20 | 0.59 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759537 | 1.00 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL23143202 | 1.00 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL7711868 | 0.95 | PTPN1 (0.89) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL673426 | 0.91 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL21385358 | 0.91 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL30075246 | 0.91 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL29759510 | 0.90 | PTPN1 (0.79) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL23143194 | 0.90 | PTPN1 (0.79) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL29759541 | 0.90 | PTPN1 (0.79) | PTPN1HNF4APTPN6PTPN2ACMSD | |
| SCHEMBL6266629 | 0.89 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629382-B2 | Therapy | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-05-19 | — | — | US | claimed |
| US-20220362265-A1 | THERAPY | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2022-11-17 | — | — | US | claimed |
| US-12629382-B2 | Therapy | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-05-19 | — | — | US | disclosed |
| US-20220362265-A1 | THERAPY | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629382-B2 | Therapy | NR3C1, MGMT, GRM3 | PTPN1 828/4885HNF4A 1192/4885PTPN6 1009/4885 |
| US-20220362265-A1 | THERAPY | GRM3, GLRX3, CBR3 | PTPN1 1583/4885HNF4A 1505/4885PTPN6 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.